Moderna's medium-term downtrend is forming as whale accumulation steadily falls, now at 16.4%. Momentum levels at $45.7, $47.4 and $52.4 are the support to watch if the decline deepens, after the volatility indicator marked the top near $80. x.com 

Moderna has almost 40% downside to its average analyst price target of $119.56, which makes the sudden rush to buy it hard to explain. x.com 

Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com 

Moderna is a stock to bet against. x.com 

Moderna looks like a risky hold over the weekend after a rough week and a potential secondary-offering overhang. x.com 

Moderna could rise further with strong call flow showing, but it is getting close to a top expected in late October or early November; take profits on the way up. x.com 

Moderna remains unattractive despite forced Nasdaq-100 index buying: quarterly revenue is $145M against a $782M loss, while shares trade around $200. Citi rates it Sell with an $80 target. x.com 

Moderna's approaching October 24 data release at a Madrid conference makes some pre-event profit-taking likely. After the release, the stock could be $400, $200 or $40; the outcome is unknown. x.com 

Moderna is extremely attractive because curing cancer is a big story, but more consolidation is likely first. The weekly chart shows a wide gap between price and the upper Bollinger Band, so volatility may need another week or two to ebb before the stock possibly starts moving higher. x.com 

Moderna's customer options positioning was not bullish, and the stock subsequently flushed 20%. WizOfOps described the top 10 trades as only modestly bearish, with no solid consensus among the customers dominating the flow. x.com